Catalyst Pharmaceuticals Inc (CPRX) - Net Assets
Based on the latest financial reports, Catalyst Pharmaceuticals Inc (CPRX) has net assets worth $1.01 Billion USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($1.15 Billion) and total liabilities ($134.91 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check tangible equity quality of Catalyst Pharmaceuticals Inc to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $1.01 Billion |
| % of Total Assets | 88.24% |
| Annual Growth Rate | 54.22% |
| 5-Year Change | 361.38% |
| 10-Year Change | 2327.61% |
| Growth Volatility | 897.86 |
Catalyst Pharmaceuticals Inc - Net Assets Trend (2002–2025)
This chart illustrates how Catalyst Pharmaceuticals Inc's net assets have evolved over time, based on quarterly financial data. See how many days can Catalyst Pharmaceuticals Inc fund operations to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Catalyst Pharmaceuticals Inc (2002–2025)
The table below shows the annual net assets of Catalyst Pharmaceuticals Inc from 2002 to 2025. For live valuation and market cap data, see CPRX company net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $954.27 Million | +31.15% |
| 2024-12-31 | $727.63 Million | +87.59% |
| 2023-12-31 | $387.88 Million | +29.11% |
| 2022-12-31 | $300.42 Million | +45.25% |
| 2021-12-31 | $206.83 Million | +21.95% |
| 2020-12-31 | $169.60 Million | +93.54% |
| 2019-12-31 | $87.63 Million | +72.55% |
| 2018-12-31 | $50.78 Million | -37.28% |
| 2017-12-31 | $80.96 Million | +105.97% |
| 2016-12-31 | $39.31 Million | -29.14% |
| 2015-12-31 | $55.48 Million | +57.41% |
| 2014-12-31 | $35.24 Million | +64.75% |
| 2013-12-31 | $21.39 Million | +46.29% |
| 2012-12-31 | $14.62 Million | +288.81% |
| 2011-12-31 | $3.76 Million | -31.84% |
| 2010-12-31 | $5.52 Million | -27.57% |
| 2009-12-31 | $7.62 Million | -27.86% |
| 2008-12-31 | $10.56 Million | -35.30% |
| 2007-12-31 | $16.32 Million | -17.76% |
| 2006-12-31 | $19.85 Million | +4345.31% |
| 2005-12-31 | $446.46K | +279.72% |
| 2004-12-31 | $117.58K | +161.93% |
| 2002-12-31 | $44.89K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Catalyst Pharmaceuticals Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 47418800000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | $474.19 Million | 49.69% |
| Common Stock | $123.00K | 0.01% |
| Other Components | $479.96 Million | 50.30% |
| Total Equity | $954.27 Million | 100.00% |
Catalyst Pharmaceuticals Inc Competitors by Market Cap
The table below lists competitors of Catalyst Pharmaceuticals Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Grand Canyon Education Inc
NASDAQ:LOPE
|
$3.83 Billion |
|
First BanCorp.
NYSE:FBP
|
$3.83 Billion |
|
HC Semitek Corp
SHE:300323
|
$3.83 Billion |
|
Mr D I Y Group M Bhd
KLSE:5296
|
$3.83 Billion |
|
Netwealth Group Ltd
AU:NWL
|
$3.83 Billion |
|
Henan Pinggao Electric Co Ltd
SHG:600312
|
$3.82 Billion |
|
BancFirst Corporation
NASDAQ:BANF
|
$3.82 Billion |
|
Qingdao Hanhe Cable Co Ltd
SHE:002498
|
$3.82 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Catalyst Pharmaceuticals Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 727,632,000 to 954,268,000, a change of 226,636,000 (31.1%).
- Net income of 214,326,000 contributed positively to equity growth.
- Share repurchases of 25,300,000 reduced equity.
- Other comprehensive income decreased equity by 64,000.
- Other factors increased equity by 37,674,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $214.33 Million | +22.46% |
| Share Repurchases | $25.30 Million | -2.65% |
| Other Comprehensive Income | $-64.00K | -0.01% |
| Other Changes | $37.67 Million | +3.95% |
| Total Change | $- | 31.15% |
Book Value vs Market Value Analysis
This analysis compares Catalyst Pharmaceuticals Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 4.18x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 1647.35x to 4.18x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2002-12-31 | $0.02 | $31.35 | x |
| 2004-12-31 | $0.04 | $31.35 | x |
| 2005-12-31 | $0.07 | $31.35 | x |
| 2006-12-31 | $2.58 | $31.35 | x |
| 2007-12-31 | $1.30 | $31.35 | x |
| 2008-12-31 | $0.81 | $31.35 | x |
| 2009-12-31 | $0.51 | $31.35 | x |
| 2010-12-31 | $0.30 | $31.35 | x |
| 2011-12-31 | $0.17 | $31.35 | x |
| 2012-12-31 | $0.49 | $31.35 | x |
| 2013-12-31 | $0.47 | $31.35 | x |
| 2014-12-31 | $0.55 | $31.35 | x |
| 2015-12-31 | $0.69 | $31.35 | x |
| 2016-12-31 | $0.47 | $31.35 | x |
| 2017-12-31 | $0.94 | $31.35 | x |
| 2018-12-31 | $0.49 | $31.35 | x |
| 2019-12-31 | $0.83 | $31.35 | x |
| 2020-12-31 | $1.60 | $31.35 | x |
| 2021-12-31 | $1.92 | $31.35 | x |
| 2022-12-31 | $2.70 | $31.35 | x |
| 2023-12-31 | $3.41 | $31.35 | x |
| 2024-12-31 | $5.82 | $31.35 | x |
| 2025-12-31 | $7.50 | $31.35 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Catalyst Pharmaceuticals Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 22.46%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 36.39%
- • Asset Turnover: 0.53x
- • Equity Multiplier: 1.16x
- Recent ROE (22.46%) is above the historical average (-87.85%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2002 | -570.19% | 0.00% | 0.00x | 2.49x | $-260.43K |
| 2004 | -459.12% | 0.00% | 0.00x | 1.58x | $-551.58K |
| 2005 | -404.37% | 0.00% | 0.00x | 1.77x | $-1.85 Million |
| 2006 | -13.75% | 0.00% | 0.00x | 1.04x | $-4.71 Million |
| 2007 | -25.36% | 0.00% | 0.00x | 1.02x | $-5.77 Million |
| 2008 | -100.04% | 0.00% | 0.00x | 1.14x | $-11.62 Million |
| 2009 | -95.07% | 0.00% | 0.00x | 1.05x | $-8.00 Million |
| 2010 | -72.61% | -819.36% | 0.08x | 1.06x | $-4.56 Million |
| 2011 | -169.94% | 0.00% | 0.00x | 1.66x | $-6.77 Million |
| 2012 | -27.88% | 0.00% | 0.00x | 1.15x | $-5.54 Million |
| 2013 | -56.82% | 0.00% | 0.00x | 1.19x | $-14.29 Million |
| 2014 | -44.01% | 0.00% | 0.00x | 1.25x | $-19.03 Million |
| 2015 | -36.47% | 0.00% | 0.00x | 1.08x | $-25.78 Million |
| 2016 | -45.98% | 0.00% | 0.00x | 1.06x | $-22.00 Million |
| 2017 | -22.74% | 0.00% | 0.00x | 1.05x | $-26.51 Million |
| 2018 | -66.96% | -6800.70% | 0.01x | 1.19x | $-39.08 Million |
| 2019 | 36.37% | 31.16% | 0.91x | 1.28x | $23.11 Million |
| 2020 | 44.21% | 62.97% | 0.62x | 1.13x | $58.02 Million |
| 2021 | 19.09% | 28.03% | 0.59x | 1.15x | $18.80 Million |
| 2022 | 27.65% | 38.79% | 0.57x | 1.25x | $53.04 Million |
| 2023 | 18.41% | 17.93% | 0.85x | 1.21x | $32.62 Million |
| 2024 | 22.52% | 33.33% | 0.58x | 1.17x | $91.13 Million |
| 2025 | 22.46% | 36.39% | 0.53x | 1.16x | $118.90 Million |
Industry Comparison
This section compares Catalyst Pharmaceuticals Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $296,451,843
- Average return on equity (ROE) among peers: -36.17%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Catalyst Pharmaceuticals Inc (CPRX) | $1.01 Billion | -570.19% | 0.13x | $3.83 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $81.00 Million |
| Abcellera Biologics Inc (ABCL) | $1.15 Billion | -12.70% | 0.29x | $1.55 Billion |
| Abeona Therapeutics Inc (ABEO) | $-17.08 Million | 0.00% | 0.00x | $321.39 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $-18.59 Million | 0.00% | 0.00x | $155.29 Million |
| Abpro Holdings, Inc. (ABP) | $-75.73 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $1.01 Billion |
| Arbutus Biopharma Corp (ABUS) | $97.37 Million | -71.81% | 0.35x | $831.63 Million |
| ABVC Biopharma Inc (ABVC) | $2.46 Million | -172.46% | 1.68x | $33.54 Million |
| Abivax SA American Depositary Shares (ABVX) | $455.01 Million | -73.87% | 0.28x | $7.77 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $1.23 Billion | 31.86% | 0.27x | $3.59 Billion |
About Catalyst Pharmaceuticals Inc
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing medicines for patients living with rare diseases in the United States. It offers Firdapse for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); Fycompa, a novel non-competitive selective antagonist at the postsynaptic ionotropic alpha-amino-3-hydroxy-5-met… Read more